Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter? International Journal of Antimicrobial Agents

on behalf of the ICONA Foundation Study Network

Research output: Contribution to journalArticlepeer-review

Abstract

Our aim was to evaluate the association between recent eGFR values and risk of switching from TDF to TAF or dual therapy (DT) in real life. HIV-positive patients achieving HIV-RNA ≤50 copies/mL for the first time after starting a TDF-based regimen were included. Kaplan–Meier (KM) curves and Cox regression models were used to estimate the time from TDF to switch to TAF or DT. 1486 participants were included: median (IQR) age 36 (30–42) years; baseline CKD-EPI eGFR 99.92 (86.47–111.4) mL/min/1.73m2. We observed a consistently higher proportion of people with HIV-RNA ≤50 copies/mL who switched from TDF to TAF rather than to DT. By competing risk analysis, at 2 years from baseline, the probability of switching was 3.5% (95% CI 2.6–4.7%) to DT and 46.7% (42.8–48.5%) to TAF. A significantly higher probability of switching to TAF was found for patients receiving INSTI at baseline versus NNRTIs and PI/b [KM, 65.6% (61.7–69.4%) vs. 4.0% (1.8–6.1%) and 59.9% (52.7–67.2%), respectively; P < 0.0001]. eGFR <60 mL/min/1.73m2 both as time-fixed covariate at baseline or as current value was associated with a higher risk of switching to DT [aHR 6.68 (2.69–16.60) and 8.18 (3.54–18.90); P < 0.001] but not to TAF-based cART [aHR 0.94 (0.39–2.31), P = 0.897; and 1.19 (0.60–2.38), P = 0.617]. Counter to our original hypothesis, current eGFR is used by clinicians to guide switches to DT but does not appear to be a key determinant for switching to TAF. © 2020
Original languageEnglish
Article number106154
JournalInt. J. Antimicrob. Agents
Volume56
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • Antiretroviral therapy
  • Dual therapy
  • eGFR
  • HIV
  • Tenofovir alafenamide
  • Tenofovir disoproxil fumarate
  • tenofovir alafenamide
  • tenofovir disoproxil
  • adult
  • Article
  • clinical evaluation
  • cohort analysis
  • disease association
  • drug effect
  • drug substitution
  • drug withdrawal
  • estimated glomerular filtration rate
  • female
  • high risk patient
  • human
  • Human immunodeficiency virus 1 infection
  • lack of drug effect
  • major clinical study
  • male
  • observational study
  • priority journal
  • risk assessment
  • treatment planning
  • virus load

Fingerprint Dive into the research topics of 'Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter? International Journal of Antimicrobial Agents'. Together they form a unique fingerprint.

Cite this